This painting company has been stable, but they have seen sustained growth and have been one of the fastest growing small business painting companies in the Vancouver/Portland area. Starting in 2013, annual had already eclipsed half a million by 2019. With a work-from-home office, this business provides the ability to manage safely out of your own home or to be able to choose your ideal location to rent. Strong customer ratings and consistently high levels of service have made this an ideal business for anyone looking to establish a presence in the painting industry or to expand your current painting business territory and customer base. Detailed Information Employees:2 FTE Support & Training: Seller will negotiate a transition period Reason for Selling: Relocation

Founded in 2011, the Company is a niche consulting and advisory firm serving in cell therapy, gene and gene-modified cell therapies, other regenerative medicines, tissue engineering, and cell-based drug discovery. The company's core focus is to improve cell & gene therapy innovations by providing consulting services for improving business strategy and achieving major regulatory milestones for companies. The Company has created a one-stop shop for all aspects of cell therapy and gene therapy, including quality checks, regulatory meetings, and submissions with the help of leading experts worldwide. The leadership has a unique combination of experience in the academic, biotech industry, government/FDA, and consulting. They serve biotech, pharma companies, consulting services for healthcare providers, subcontracts for other consulting firms, and contracts with government organizations, which enables them to have 6x+ growth in net income from 2019 2021, i.e., $179,000 to $1,095,000 with the help of 110+ customers served over the past six years. The Company's plan is to consummate a transaction with a supportive growth partner in order to accelerate the company's cell and gene therapy market growth by interacting with industry, academia, government, and other international stakeholders in cell & gene therapies and cell-based drug discovery. NDA is required to secure comprehensive Confidential Information Memorandum (CIM) crafted by ProNova Partners. Detailed Information Facilities: Has headquarters in US contractors operate nationwide / portable / buyer can be located worldwide. Competition: A few competitors in the space are in the field but the Company provides best in class services for its respective niche(s). Growth & Expansion: Continually grow and become more profitable with the help of experts that supports preclinical, clinical, and commercial advisory in the manufacturing, regulatory affairs, Quality/GxP, and M&A arenas. Financing: If the price and deal structure is right. Support & Training: Long term transition, Seller wishes to smooth the transition to maximize success with the Company post-closing and spearhead continued growth. Reason for Selling: Growth.

Our client is offering a next generation, patented medical device for the treatment of internal hemorrhoids. The procedure is painless, non-invasive, requires no anesthesia, is conducted in under 2 minutes, and can be performed in any medical setting: a doctor's office, a surgery center, an endo suite, or a hospital. Our client's product is a small, disposable, medical device that eliminates hemorrhoids. A physician uses this device by deploying a tiny rubber band on the base of the hemorrhoid. This procedure is known as rubber band ligation, and it is the #1 recommended treatment for internal hemorrhoids by the American College of Gastroenterology. Patients no longer need to use ineffective creams or receive painful, invasive surgery. Our client's device offers a permanent solution for their hemorrhoids. The device is currently manufactured in the USA through an FDA approved, ISO 13485 contract manufacturer, who specializes in medical devices. The device is sold directly to physicians of different specialties, including gastroenterologists, colorectal surgeons, GYNs, urologists and primary care physicians. The biggest targeted audience are gastroenterologists. NDA is required to secure comprehensive Confidential Information Memorandum. Growth and epansion: Nearly half of adults over the age of 50 will develop symptomatic hemorrhoids. In the U.S. alone, an estimated 60,000,000 people have experienced hemorrhoid symptom(s) at some point in their lives. Annually, over 20,000,000 people in the U.S. use an over-the-counter hemorrhoid treatment and 75% report a reoccurrence. These patients no longer need to use ineffective creams or receive painful, invasive surgery. Our client's device offers a permanent solution for their hemorrhoids. Financing is if the price and deal structure is right, and support and training is provided as required. Facilities are Outlined in CIM. Reason for selling is that the owners wish to move on to other projects.

The Company has proprietary technology that addresses a leading cause of maternal death (76,000) and fetal death (500,000) annually worldwide. 8% of pregnancies in the US and 14% worldwide have diagnoses that would be vastly improved by worldwide commercialization of the Company's proprietary device. A very low risk procedure that both provides quality of life improvement for the mother & baby and lowers health care costs is a win/win/win for all involved. Existing collaborations with major manufacturers coupled with a current expedited approval process with the FDA presents a tremendous opportunity for individuals or private equity groups seeking a transformative investment into a feel-good biotech story with exceptional legs and a vast runway with nearly unlimited upside. Able to work with groups/individuals in tranches of $500k to $1M to advance into the pilot clinical study, $2-$3MM for the pivotal clinical study towards market approval in the US. They will seek direct sales with partnered hospitals, licensing / partnership deals could utlimately yield the balance of funding to fully deploy a commercial version of the technology. NDA is required for comprehensive Confidential Information Memorandum (CIM) crafted by us. Detailed Information Competition: No current option available besides bed rest. Growth & Expansion: Huge market potential. Support & Training: Full team included. Reason for Selling: Seeking supportive capital partners to take to the next level(s). .

Our client opportunity was developed and founded by two giants of the industry. One of the founders brings a thirty-year career with the New York Football Giants in various director and executive capacities. He founded and chaired the NFL Video Directors Executive Committee, has multi-Emmy winning shows, multiple Telly and Aurora awards, three Super Bowl rings, and was a technical innovator on the team that created instant replay. The other founder was head of programming at Disney Channel for eleven years where the channel won over 100 Emmy/Ace awards and grew profits 20% per year for 10 years. He co-founded Tennis Channel managing launch and operations, and has launched over 30 TV channels including streaming channel Players TV and 18 Short Movie Channels worldwide. Our client has secured distribution agreements with major streaming platforms including Roku, Apple TV, Amazon Fire TV, Samsung TV, Mobile Users (Apple iOS and Android OS), and All Web Applications. Our client currently offers 50 hours of programming to viewers and is available on 500,000,000 devices with active streaming capability. Our client’s opportunity is currently operating. It is an English-language Italian and Italian American focused streaming channel and media brand targeting 30 million Italian Americans and 160 million Italophiles in the U.S. Our client has soft launched as a proof of concept and is building viewership through this ubiquitous distribution platform. Programming inventory consists of 50 hours of current programming featuring original and acquired programs in categories of cooking, Italian American lifestyles, culture, travel, comedy, inspirational, and documentaries. BritBox, a comparable British programming streaming service, recently sold 50% to the BBC for $322 million yielding a $644 million valuation. Our client targets a significantly larger audience of approximately 200 million Italian Americans and Italophiles through AI advertising, sponsorship, and e-commerce integration. The owners have an ecommerce platform in development through which viewers can purchase select Italian exquisite products and services, travel opportunities and other products featured on the channel. NDA required to receive comprehensive Confidential Information Memorandum (CIM) crafted by ProNova Partners.

The Company operates in the healthcare technology space with a focus on addressing gaps in dementia and Alzheimer’s care. The company has built an ecosystem where data is collected from caregivers and patients in real-time and pushed into physicians’ EHR/EMR systems to monitor the effectiveness of the prescribed treatment plan. Alzheimer’s Disease and other dementia is the first condition that the platform will be focused on. Its platform supports physicians in managing patients through tools that enable remote monitoring and data collection, allowing for more continuous oversight rather than episodic intervention. The business generates revenue through a combination of public healthcare reimbursements and collaborations with pharmaceutical and research entities. Its model emphasizes integrating digital health solutions into clinical workflows to improve patient tracking and care coordination. The Company’s target users include healthcare providers, caregivers, and researchers working with aging populations impacted by cognitive decline. NDA is required to receive comprehensive Confidential Information Memorandum (CIM) crafted by ProNova Partners.

Our client developed and operates a multi-market high-demand system capable of identifying criminal subjects in seconds. Access to the cloud-based software is subscription-based with packages ranging from $35,000 to $300,000 annually. The system generates recurring revenue from major retailers. Our client's database is fed with crime and criminal data from over 28,000 sources that update and add new data to their system every day. A global technology agreement was recently signed by a major worldwide electronics manufacturer to integrate our client's system. This significant agreement with the major worldwide electronics manufacturer expands the system from single-enterprise sales to mass-market injection via this new customer's global customer base. The enterprise was designed to bridge the long-standing gap between surveillance video and subject identification and create a next-generation system for subject intelligence. The founder tells us: 'We spent significant time and resources to identify over 28,000 data source points and go through the process to obtain, extract, scrub, and continually update records. Our system and process continued to rapidly develop, allowing further increases in data digestion while completely automating the process. We remain the largest private database of criminals in the world. We developed a multi-market high-demand system capable of identifying criminal subjects in seconds. Whether identifying subjects from surveillance video, home security cameras, video doorbell cameras, or conducting compliance and risk mitigation, our solution and its 70 million+ database is a market-first product with no competition and is used by a variety of Fortune 500 blue-chip customers. The signing of a major worldwide electronics manufacturer to a global technology partnership will add our system to their security products, creating a mass-market injection and significant ARR stream.' With a sales, marketing, and business development team comprised of only 2 people, our client focused initially on penetrating the difficult and highly competitive market of loss prevention within Fortune 500 retailers. After the proprietary system demonstrated a successful track record in identifying subjects and deterring criminal activity, our client gained immediate visibility and has since gained nearly a dozen of the world's largest retailers as clients. Our client has disrupted antiquated identification processes within several of the largest markets, attracting the attention of global manufacturers such as the major worldwide electronics manufacturer's willing to integrate their technology. Our client developed a SaaS system, which provides its '4 I's' Intelligence, Information, Investigation, and Identification. The SaaS is a completed system and is fed with crime and criminal data from over 28,000 sources that update and add new data to the system every day. Access to the cloud-based software is subscription-based with packages ranging from $35,000 to $300,000 annually. Our client's technology has been implemented by many of the largest companies in the world and is currently being integrated by one of the largest technology manufacturers in the world. The strategy is effective, and the reach of the technology is poised to be further expanded. Our client invented and made operational multiple processes and new technology. The system is not only completed and automated, but also proven in the marketplace. One of the achievements worthy of note is that our client's system was responsible for the largest Organized Retail Crime bust in US history. Our client's core competencies and strengths include the highly developed system with ownership of the largest private database of criminal subjects in the world, existing blue-chip customers, a global technology contract with a major worldwide electronics manufacturer, and a technology platform that is extremely valuable in multiple other markets that have not yet been approached. Our client's Intelligence obtains its database data from over 28,000 county, state, federal, and regulatory agency sources. Our client has automated the data digestion process to upload new records, and search/verify changed records several times per day. Once new and or changed data is recognized, an automated process will retrieve the data, categorize, and then implement into our client's system. Our client owns all processes, and websites which they will transfer in full to a buyer. Our client's 'ready to go,' profitable tech, and relationships will enable a buyer to be up and running immediately. NDA is required {LINK ABOVE} to secure comprehensive Confidential Information Memorandum (CIM) crafted by ProNova Partners. Detailed Information Facilities: N/A Growth & Expansion: See the CIM for details Financing: Offers and investment will be considered Support & Training: As needed specific terms for transition support can be negotiated. The Seller wishes to facilitate a successful and smooth transfer of the Business. Reason for Selling: To allow the business to rapidly expand world-wide

Our client operates a lean, high-margin B2B lead-generation platform dedicated to the Internet of Things sector. By leveraging a permission-based community of over 60,000 vetted IoT decision-makers and a LinkedIn Group of 20,000+ approved professionals, they deliver turnkey sponsored webinars, white-paper campaigns, and targeted email blasts—providing technology vendors with consistently qualified leads while maintaining minimal overhead through a fully remote, contractor-driven model. NDA is required for comprehensive Confidential Information Memorandum (CIM) crafted by ProNova Partners.